Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

112.47 +4.24 (+3.92%)
Streaming Delayed Price Updated: 3:15 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
65 66 Next >
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories
Benzinga 
Via Benzinga
European Union's Amended COVID-19 Vaccine Deal with Pfizer-BioNTech: Near-Monopoly Status Potential Threat to Rivals
The European Union bloc is reportedly negotiating an amended deal with Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) for around 70 million COVID-19 vaccine doses, despite the European public... 
Via Benzinga
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies. 
Via Investor's Business Daily
How To Attend BioNTech Q1 2023 Earnings Conference Call
Via Benzinga
Buy This Pharma Powerhouse With A 4% Yield
Imagine a company whose stock hit an all-time in December 2021 after soaring 50% that year. And that company’s sales doubled in the two years leading up to 2022. And its operating profits quadrupled. 
Via Talk Markets
BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023
From BioNTech SE
Via GlobeNewswire
Novavax Plummets On Downgrade: Is It The Covid Engine That Couldn't?
The company is facing a litigation headwind and continued competition. 
Via Investor's Business Daily
P/E Ratio Insights for BioNTech
Via Benzinga
7 Low-PE Ratio Blue-Chip Stocks Offering Both Quality and Value
Make your dollars go as far as possible (and relatively safely) with these low-PE ratio blue-chip stocks to buy. 
Via InvestorPlace
FDA Gives Green Signal To Second Omicron-Adapted Booster Shots For People At High Risk From Covid
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
What 12 Analyst Ratings Have To Say About BioNTech
Via Benzinga
A Look Into BioNTech Inc's Price Over Earnings
Via Benzinga
US Court Favors Moderna In COVID-19 Vaccine Patent Infringement Case With Arbutus Biopharma
Via Benzinga
Biden Administration Launches $5B Program To Boost Development Of Pan-Coronavirus Vaccine, Treatments
The White House plans to devote $5 billion to develop effective treatments and vaccines against current and future Covid variants, a Department of Health and Human Services (HHS) spokesperson and a... 
Via Benzinga
Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal
Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up... 
Via Talk Markets
Pfizer Slapped With Additional Patent Infringement Lawsuit Over Its Famed COVID-19 Shots
Via Benzinga
Bear of the Day: BioNTech
BioNTech was relatively obscure until the company partnered with pharmaceutical juggernaut Pfizer (PFE) to develop one of the first mRNA COVID-19 vaccines. 
Via Talk Markets
These Analysts Revise Price Targets On BioNTech After Q4 Results
BioNTech SE (NASDAQ: BNTX) reported a decline in sales for its fourth quarter. 
Via Benzinga
Why Shares of BioNTech Slumped Monday
The company released fourth-quarter earnings. 
Via The Motley Fool
Arbutus Biopharma and Genevant Sciences File Patent Infringement Lawsuit Against Pfizer/BioNTech
From Arbutus Biopharma Corporation
Via GlobeNewswire
BioNTech and DualityBio Form Global Strategic Partnership to Accelerate Development of Differentiated Antibody-Drug Conjugate Therapeutics for Solid Tumors
From BioNTech SE
Via GlobeNewswire
Stock Market Rallies On Micron, Alibaba, Lululemon, Ebbing Bank Fears: Weekly Review
The stock market rallied on ebbing bank fears and positive news from Micron, Alibaba and Lululemon Athletica. 
Via Investor's Business Daily
NVIDIA To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Tuesday
B of A Securities cut the price target for Fox Corporation (NASDAQ: FOXA) from $42 to $34. B of A Securities analyst Jessica Reif Ehrlich downgraded the stock from Buy to Neutral. Fox shares fell 1.8%... 
Via Benzinga
BioNTech Announces New ADS Repurchase Program
From BioNTech SE
Via GlobeNewswire
Elon Musk-Led Neuralink Seeks Human Trial Collaborators, Credit Suisse May Face Disciplinary Action, First Citizens Takeover Silicon Valley Bank: Today's Top Stories
Benzinga 
Via Benzinga
BioNTech, Coinbase Global, Pharming Group And Other Big Stocks Moving Lower On Monday
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Monday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
BioNTech Is Ripe For A Rebound In 2023
BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
BioNTech Stock Crumbles After 2023 Outlook Misses By Almost $3 Billion
For the year, BioNTech said it expects about $5.4 billion in sales of its Covid shot. 
Via Investor's Business Daily
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.